Ghosh, Subrata
Gensler, Lianne S.
Yang, Zijiang
Gasink, Chris
Chakravarty, Soumya D.
Farahi, Kamyar
Ramachandran, Paraneedharan
Ott, Elyssa
Strober, Bruce E.
Funding for this research was provided by:
Janssen Research and Development
Article History
First Online: 9 February 2019
Change Date: 22 April 2019
Change Type: Correction
Change Details: In the original publication of this article, the following correction should be noted in Table 5.
Compliance with Ethical Standards
: Each trial complied with the Declaration of Helsinki and Good Clinical Practice guidelines. Each site’s governing ethical body approved the study protocol, and all patients provided written informed consent.
: Janssen Research & Development, LLC, sponsored and funded the trials contributing data to these integrated safety analyses. The sponsor oversaw each study’s protocol development and conduct. All authors, including those employed by the sponsor, made substantive contributions to data analysis/interpretation and manuscript development, and approved the final version prior to submission. A professional medical writer paid by the sponsor assisted the authors with manuscript preparation and submission.
: All authors had full access to the study data, were involved in data interpretation, participated in manuscript preparation, and approved the final version for submission. In addition, SG planned the initial draft of the manuscript; ZY assisted with data analyses; and BS, CG, EO, and SG were involved in study conduct and data acquisition.
: Subrata Ghosh has received consulting honoraria from AbbVie, Boehringer-Ingelheim, Bristol Myers Squibb, Gilead, Janssen, Pfizer, and Takeda, and research grant support from AbbVie and GlaxoSmithKline. Lianne S. Gensler has received consulting honoraria from Janssen and Novartis, and research grant support from AbbVie, Amgen, and UCB. Zijiang Yang and Paraneedharan Ramachandran are employed by Janssen Research & Development, LLC, and Chris Gasink, Soumya D. Chakravarty, Kamyar Farahi, and Elyssa Ott are employed by Janssen Scientific Affairs, LLC, both wholly owned subsidiaries of Johnson & Johnson (J&J), and own stock/stock options in J&J. Bruce E. Strober discloses the following relationships: consultant and member of the advisory board for AbbVie, Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Celgene, Cutanea-Maruho, Dermira, Eli Lilly, Janssen, Leo, Medac, Novartis, Pfizer Inc, Sun Pharma, UCB, and Valeant (honoraria for all); investigator for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer Inc, Sun Pharma (payments to the University of Connecticut, not to Bruce Strober, MD, PhD); scientific director for CORRONA Psoriasis Registry (consulting fee); and grant support to the University of Connecticut for Fellowship Program from AbbVie, Janssen (payments to the University of Connecticut, not to Bruce Strober, MD, PhD).